Cash Flow Statement (Annual)

TSX:BCB / Cott Corp Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities Continuing Operations
  Profit Loss 86,100 59,800 41,200 52,300 22,000 16,400 20,600 -71,500 7,100
  Income Loss From Discontinued Operations Net Of Tax - - - - - - 4,900 -11,200 10,700
  Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest - - - - - - 15,700 -60,300 -3,600
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 66,200 74,000 95,300 97,700 100,800 110,700 128,300 151,100 188,600
    Amortization Of Financing Costs 1,500 2,700 3,900 3,700 2,800 2,500 4,800 500 1,900
    Amortization Of Debt Discount Premium - - - - - -400 -5,600 -5,900 -5,100
    Share Based Compensation 1,300 4,700 2,900 4,900 4,000 5,800 7,600 7,000 17,500
    Increase Decrease In Deferred Income Taxes -6,200 -17,000 3,700 -3,800 -900 65,800 22,000 -19,900 33,900
    Unrealized Gain Loss On Cash Flow Hedging Instruments - - - - - - - -9,700 300
    Gains Losses On Extinguishment Of Debt -1,500 -100 - - - - - - 1,500
    Gain Loss On Sale Of Property Plant Equipment -500 -1,100 -1,200 -1,800 -1,000 -1,700 -4,200 -6,600 -10,200
    Other Noncash Income Expense - -5,500 -4,900 400 -900 -300 9,100 -9,700 -1,900
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable -20,800 3,900 5,000 -15,000 -13,900 -1,500 3,800 3,100 8,000
    Increase Decrease In Inventories -16,000 28,400 -6,500 12,100 1,000 -12,900 -1,000 -12,900 2,000
    Increase Decrease In Prepaid Deferred Expense And Other Assets 1,600 -2,600 -5,800 300 1,300 25,200 -1,700 4,600 -900
    Increase Decrease In Other Operating Assets 1,200 1,600 700 -900 -6,100 -1,700 3,300 1,300 -2,100
    Increase Decrease In Accounts Payable And Accrued Liabilities -6,500 39,800 11,500 -2,200 -600 -6,800 16,400 3,300 7,300
  Net Cash Provided By Used In Operating Activities Continuing Operations - - - 173,000 154,900 56,700 131,100 145,500 176,000
Net Cash Provided By Used In Investing Activities Continuing Operations
  Payments To Acquire Businesses Net Of Cash Acquired - 507,700 34,300 9,700 11,200 798,500 24,000 959,400 35,500
  Payments To Acquire Property Plant And Equipment 32,300 44,000 48,800 69,700 55,600 46,700 69,600 95,100 121,300
  Payments To Acquire Intangible Assets 1,600 4,200 5,700 5,200 5,900 6,900 3,000 4,200 5,600
  Proceeds From Sale Of Property Plant And Equipment 1,700 1,200 400 2,300 200 1,800 30,000 5,700 7,800
  Payments For Proceeds From Other Investing Activities - - 1,800 - - - 1,200 -400 -1,000
  Net Cash Provided By Used In Investing Activities Continuing Operations - - - -80,400 -71,600 -850,300 -66,600 -1,052,600 -153,600
Net Cash Provided By Used In Financing Activities Continuing Operations
  Repayments Of Long Term Debt 265,500 18,700 6,800 3,300 220,800 393,600 3,700 500 101,500
  Proceeds From Issuance Of Long Term Debt 211,900 375,000 - - - 1,150,000 - 498,700 750,000
  Proceeds From Lines Of Credit 768,100 366,500 224,100 24,500 131,900 959,000 994,500 2,403,200 -
  Repayments Of Lines Of Credit 856,600 379,000 231,900 24,500 82,100 779,600 1,101,800 2,320,300 -
  Payments Of Debt Extinguishment Costs - - - - - - - - 7,700
  Payments Of Debt Issuance Costs - - - - - - - 10,100 11,100
  Proceeds From Issuance Of Common Stock 47,500 71,100 300 - - - 143,100 366,800 3,500
  Payments For Repurchase Of Common Stock - - - 300 13,000 12,100 800 5,700 3,800
  Payments Of Ordinary Dividends - - - 5,800 21,900 22,800 31,000 31,400 33,400
  Proceeds From Payments For Other Financing Activities -100 - - - - -300 - 100 500
  Net Cash Provided By Used In Financing Activities Continuing Operations - - - -16,200 -213,300 835,700 -37,500 807,100 596,500
Discontinued Operation Alternative Cash Flow Information
  Cash Provided By Used In Operating Activities Discontinued Operations - - - - - - 123,500 124,300 102,700
  Cash Provided By Used In Investing Activities Discontinued Operations - - - - - - -33,100 -44,000 -44,700
  Cash Provided By Used In Financing Activities Discontinued Operations - - - - - - -122,600 68,600 -643,400
  Net Cash Provided By Used In Discontinued Operations - - - - - - -32,200 148,900 -585,400
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - -3,900 -7,900 6,300
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - -9,100 41,000 39,800
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations - - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations - - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - 157,900
Cash Flow Noncash Investing And Financing Activities Disclosure
  Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction - - - - 1,200 1,500 - 500 600
  Dividends Payable Current And Noncurrent - - - - - - - - -
  Capital Expenditures Incurred But Not Yet Paid - - - - 3,900 7,800 700 3,100 10,900
Supplemental Cash Flow Information
  Interest Paid 23,800 22,800 53,800 51,000 50,900 45,500 34,900 48,500 81,600
  Income Taxes Paid Net 11,000 -24,300 1,300 -7,700 100 2,500 2,500 3,300 1,900

Peers - Bottled and Canned Soft Drinks and Carbonated Waters (2086)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...